What's Hot
View all perspectives
David Liew drdavidliew
3 years 1 month ago
To be clear, for IBM: resignation 'not that long ago' = yesterday. Early days I know, but nothing like a plausible, feasible target to bring hope
@UpToDate screenshot
exciting times at #ACR21 @RheumNow https://t.co/WAEUtQagym
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 L10 TRAIL1: Pirfenidone for RA-ILD
⭐️Low pt enrollment due to pandemic, 1/2 of planned trial size
▶️ Unable to meet primary endpt (composite death+FVC) but met FVC markers. Most pronounced in UIP patterns on HRCT
@Rheumnow https://t.co/HB7N9Wl9Dn https://t.co/muBEguAAja
Mrinalini Dey DrMiniDey
3 years 1 month ago
#Sleep disturbance is common in #RA but does it correlate with disease activity?
Results from >100 RA pts suggest yes.
Many reported sleep disturbances, associated with both incr patient & physician-assessed disease activity.
Abs#1666 #ACR21 @RheumNow
https://t.co/ud2uMf25cI https://t.co/BE4UHPB0f1
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
Dr. John Cush RheumNow
3 years 1 month ago
Predicting RA, and Treatment of Subclinical Arthritis
Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis.
https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU
Richard Conway RichardPAConway
3 years 1 month ago
My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow
Richard Conway RichardPAConway
3 years 1 month ago
Watch back our recap of the best from Day 2 of #ACR21 in the @RheumNow daily panel. With @AurelieRheumo @RheumNow @Yuz6Yusof @bella_mehta @_Castillo_Pedro https://t.co/ORTbV61c2C
Richard Conway RichardPAConway
3 years 1 month ago
Watch my video of #ACR21 Abstract 1456, a double blind RCT of CBD for hand OA and PsA @RheumNow https://t.co/p0IiYzYe2m
Richard Conway RichardPAConway
3 years 1 month ago
Watch my video discussion of #ACR21 abstract 564 from @KronzerMD @jeffsparks on the association of upper airways disease with incident RA. https://t.co/Nkg9Yl9yYT @RheumNow
Richard Conway RichardPAConway
3 years 1 month ago
This case is from the hypereosinophilic syndrome talk. This was NOT EGPA! It was cancer. Be careful! #ACR21 @RheumNow https://t.co/UhdpeHBfOE
Mrinalini Dey DrMiniDey
3 years 1 month ago
What is the effect of long-term #steroid use on major adverse #cardiovascular events (MACE)?
Find out in my video summary of abstract #1428 which was presented yesterday by @BethIWallace
Read here👉🏼https://t.co/fCM3m04ruS
Watch here👉🏼https://t.co/TLerQT7XnG
#ACR21 @RheumNow
Aurelie Najm AurelieRheumo
3 years 1 month ago
Avoid IFX drug holidays!
In this study 400+ pts
Dvlpmt of ADAs associated w/
▶️RA vs. SPA OR 2.1
▶️Smoking OR 1.8
▶️Drug holidays > 11 weeks OR 4.1
▶️High DA OR 1.5
while
◀️Concomitant IS drug OR 0.4
◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh
Poster Hall